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Abstract
Background: A pilot evaluation to assess the safety and possible benefits of TLC C-53, (prostaglandin E associated with egg1
phosphatidylcholine liposomes) in acute respiratory exacerbations in children with cystic fibrosis (CF). Methods: Randomised,
double-blind, placebo-controlled study in 20 P. aeruginosa colonised patients. All received intravenous antibiotics. Subjects were
given a rising dose of TLC C-53 (0.15–1.8 mgykg) by 4=1-h infusions. Primary outcome measures were sputum IL-6, IL-8 and
sputum neutrophil elastase. The rate of decline in lung function was determined at 6 weeks post-therapy as was the interval until
the next respiratory exacerbation requiring intravenous antibiotic therapy. Results: Analysis of primary and secondary outcome
measures failed to show any significant differences between the two groups, although trends favoured the treated group. Decline
in lung function over 6 weeks favoured the TLC C-53 group (FEV mean difference 4.3%, 95% CIsy6.8, 15.4%). Time to1
next exacerbation also favoured the TLC C-53 group with a mean time to exacerbation for TLC C-53 of 26.0 weeks against 11.9
weeks. Conclusions: A larger multi-centre trial of TLC C-53 as an adjunct to antibiotic therapy in respiratory exacerbations in
CF would appear warranted.  2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Cystic fibrosis (CF) is characterised by an increase
in sweat Cl concentration, exocrine pancreatic insuf-y
ficiency, male infertility and predisposition to respiratory
infection. The latter leads to progressive lung disease
and is the major cause of morbidity and mortality.
Antibiotic therapy can prevent, eradicate or delay chron-
ic lower airway infection and improve survival w1x.
Nevertheless, the majority of patients with CF develop
chronic endobronchial infection with P. aeruginosa and
suffer a steady decline in respiratory function w2x. There
is increasing evidence that immune mediators, particu-
larly neutrophil proteinases, contribute to lung tissue
damage and impair local host defence mechanisms,
preventing the clearance of infection w3,4x. Treatment
with anti-inflammatory agents including high-dose cor-
ticosteroids w5x and ibuprofen w6x have both been shown
to slow the progression of pulmonary disease, suggesting
that blunting the immune response might preserve lung
function.
*Corresponding author. Fax: q44-114-275-9947.
In the chronically infected CF lung, persistent neutro-
phil stimulation by host and bacterial elements leads to
high concentrations of neutrophil elastase w7x, whereas,
protective a-1 proteinase inhibitor and secretory leuco-
protease inhibitor are enzymatically degraded w8,9x.
Neutrophil elastase not only degrades nearly all struc-
tural proteins of the lung but also exerts toxic effects
on endothelial cells w10x, decreases ciliary motility and
may inactivate key components of the immune system
w11x. In addition, neutrophil elastase appears to recruit
polymorphs to the lung by upregulating IL-8 synthesis
by bronchial epithelial cells w12x.
TLC C-53 is a preparation in which prostaglandin
E is associated with egg phosphatidylcholine liposomes.1
It has been shown to inhibit neutrophil activation,
primarily through downregulation of CD11byCD18
expression and neutrophil adherence w13x. Moreover,
animal studies have demonstrated improved outcomes
in neutrophil-mediated models of inflammation w14x.
Additionally, liposomes are opsonised with fibronectin
resulting in their targeting to venous endothelium with
an associated downregulation of the ICAM-1 receptor
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Table 1
Comparison of demographic features
TLC C-53 Placebo Mean 95% CI P-value
(ns9) (ns11) diff. of diff.
Age 13.1 14.2 y1.1 (y5.6, 2.5) 0.54
Weight 40.6 41.0 y0.4 (y13.6, 12.8) 0.91
Height 152.7 151.6 1.1 (y16.9, 19.1) 0.94
S score 62.6 58.7 3.9 (y9.7, 17.5) 0.90
FEV %1 67.3 57.7 9.6 (y2.8, 22.0) 0.44
FVC% 78.6 70.9 7.7 (y3.6, 19.0) 0.50
Sex 6F, 3M 6F, 5M
Table 2
Analysis of serial measurements: area under the curve
Measurement TLC C-53 Placebo Mean 95% CI of P-value
(ns9) (ns11) diff. diff.
a: Spirometry
FEV1 25.7 29.0 y3.3 (y18.2, 11.6) 0.67
FVC 33.9 33.6 0.3 (y12.7,13.3) 0.99
b: Patient VAS scores
Appetite 90.7 64.7 26.0 (y12.8, 64.8) 0.21
Sputum production 70.1 59.2 10.9 (y21.3, 43.1) 0.52
Cough (frequency) 40.5 33.7 6.8 (y 0.9, 14.5) 0.10
Quality of life 30.4 28.3 2.1 (y3.3, 7.5) 0.44
Physical activity 18.3 17.0 1.3 (y1.3, 3.9) 0.35
Ease of breathing 32.2 31.4 0.8 (y7.0, 8.6) 0.84
c: Clinician VAS scores
Breathing 181.4 166.8 14.6 (y40.8, 70.0) 0.52
Observed activityy
capability 106.9 106.8 0.1 (y17.5, 17.6) 0.99
General appearance 88.3 92.8 y4.5 (y21.3, 12.3) 0.60
Response to therapy 181.5 204.0 y22.5 (y54.8, 9.8) 0.19
Data represent average% change over 7 days after adjusting for baseline values. Values in bold type favour treatment group; example interpre-
tation: average improvement (TLC C-53 vs. placebo) for patients’ appetite was 26%).
on post-capillary venules w13x, thus limiting neutrophil
adhesion and vascular extravasation. The liposome moi-
ety of TLC C-53 appears to facilitate the anti-inflam-
matory neutrophil-modulating effect of PGE shifting1
the balance of activity from pro to anti-inflammatory
w15x. This pilot evaluation aims to assess the safety and
possible benefits of TLC C-53 in acute respiratory
exacerbations in children with cystic fibrosis (CF).
2. Patients and methods
Twenty P. aeruginosa colonised patients with CF
admitted to the Sheffield Children’s Hospital with an
acute respiratory exacerbation were randomised into a
double-blind, placebo-controlled study. The study was
approved by the local Research Ethics Committee.
All patients received standard care including intrave-
nous antibiotics. Subjects were given a rising dose of
TLC C-53 (0.15–1.8 mgykg) by 4=1-h infusions;
patients in the placebo arm received 5% dextrose over
7 days. Primary outcome measures were sputum IL-6,
IL-8 and sputum neutrophil elastase. A clinical assess-
ment was carried out by the treating clinician and
physiotherapist and scored using a visual analogue scale
(VAS). Also evaluated were serum IL-6, IL-8, a-1 anti-
protease neutrophil-elastase complex, lung function, spu-
tum production and patients assessment of well-being
by VAS. The rate of decline in lung function was
determined at 6 weeks post therapy as was the interval
until the next respiratory exacerbation requiring intra-
venous antibiotic therapy.
Analysis of covariance was used for between group
comparisons with data presented as percent change from
mean with 95% confidence intervals. Immunological
data were skewed, thus summary measures were ana-
lysed by Mann–Whitney U-test by comparing medians;
a nominal significance level of 5% was assumed.
3. Results
The study medication was well tolerated with no
serious adverse events documented during the trial.
Patient demographics are recorded in Table 1. It was
noted that both FEV and FVC were lower in the1
placebo groups, thus, these differences were taken into
account in the statistical comparisons. Analysis of both
primary and secondary outcome measures failed to show
any significant differences between the two groups,
although trends favoured the treated group.
A comparison of the variables by the area under the
curve (AUC) method is presented in Table 2. Data on
spirometry favoured placebo for FEV and TLC C-531
for FVC (Table 2a). All patients responses, as measured
by visual analogue scales, showed an improvement in
favour of the treatment group (Table 2b). Clinical VAS
scores were split between TLC C-53 and placebo (Table
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Table 3
Analysis of immunological data: change in activity
Variable TLC C-53 Placebo P-value
Median median
Serum IL-8 y31.4 129.0 0.81
a1 elastase 38.5 26.4 0.08
Sputum IL-8 I27.7 y7.6 0.54
Sputum neut. y8.2 y8.7 0.90
Statistical comparison by Mann–Whitney U-test; values in bold
type favour treatment group. Negative sign indicates reduction from
baseline).
2c). Most of the immunological data showed greater
improvement in the treatment group (Table 3).
Both FEV and FVC were measured 6 weeks post1
treatment (or nearest time to 6 weeks). Lung function
declined in both groups over time but comparing the 7-
day and 6-week time points favoured the TLC C-53
group. The mean reduction from 7 days to 6 weeks for
FEV was 28.2% in the treatment group against 32.5%1
for controls (adjusting the analysis for baseline values
in an analysis of covariance with baseline values being
the covariate), hence, the mean difference was 4.3%
(95% CIsy6.8, 15.4%). For FVC the mean reduction
was 13.4% for the TLC C-53 group and for the placebo
group, 14.9%; a mean difference of 1.5% (95% CIsy
7.0, 10.0%). Time to next exacerbation also favoured
the TLC C-53 group with a mean time to exacerbation
of 26.0 weeks against 11.9 weeks (mean differences
14.1 weeks, 95% CIsy0.4, 28.8) for the placebo
group. Mean and median times between exacerbations
in the 12 months prior to randomisation were also
calculated for both groups. For the liposome treated
group, mean times7.3 weeks (medians6.8); for the
placebo group, mean times14.8 weeks (medians12.6
weeks).
4. Discussion
This initial evaluation of TLC C-53 in CF patients
has shown that the intervention is safe and has possible
beneficial short- and long-term effects. Our hypothesis
was that the anti-inflammatory action of TLC C-53,
used in the acute situation, would lead to a reduction in
the inflammatory response and more rapid improvement
in lung function. Quantitating this effect by measurement
of inflammatory markers and FEV yFVC proved only1
partly successful, probably reflecting the intense immu-
nological activity occurring continually within the lungs
of these P. aeruginosa colonised patients w16x. We were
unable to demonstrate the ability of TLC C-53 to
modulate infiltration of neutrophils into the airways and
lung tissue, effects previously shown in animal studies
and in an encouraging phase II trial in adults with acute
respiratory distress syndrome (ARDS) w17x. However,
there was an indication that the IL-8 levels in both
serum and sputum fell with the intervention. IL-8 is an
important chemotactic factor in sputum of patients with
cystic fibrosis, bronchiectasis, and chronic bronchitis,
and is believed to account, at least in part, for neutrophil
recruitment into airways of patients with these diseases
w18x.
A possible down regulation of IL-8 may also be
relevant to the increase in mean time to the next
respiratory exacerbation seen in the intervention group
(26.0 weeks vs. 11.9 weeks). This was unexpected and
perhaps more surprising given the differences between
groups in respiratory exacerbation frequency in the 12
months prior to randomisation (mean antibiotic-free
period wplacebo groupx 14.8 weeks vs. 7.3 weeks for
the treatment group).
Previous studies of anti-inflammatories in CF have
demonstrated long-term improvements on therapy. Auer-
bach et al. w4x, found significant advantages with alter-
nate day steroid compared with placebo in terms of
height, weight, vital capacity, FEV and serum IgG1
assessed over 4 years w5x. The prednisone-treated group
also required fewer admissions to hospital for respiratory
exacerbations. Konstan et al., on the other hand, failed
to demonstrate a difference in 4-year hospitalisation
rates in ibuprofen treated patients, although the annual
rate of change in FEV was slower in treated patients1
and weight gain and chest-radiograph score were
improved w6x. The difference in rates of decline in lung
function in our study compared with Konstan et al.
(FEV 4.3%, FVC 1.5%) may reflect the increased1
severity of lung disease (mean FEV 67% predicted) in1
our patients.
The results of this pilot evaluation suggest a possible
role for liposomal prostaglandin E in acute respiratory1
exacerbations in patients with CF. The intervention
proved safe but the sample was too small to detect
significant differences between groups. This is not unex-
pected in a pilot study where power calculations were
not carried out. However, it is possible to use these data
to calculate the sample size required to power a larger
study w19x. Thus, pooled standard deviation for time to
next exacerbation (for example) was 21.4 units. To
show an improvement of 14.1 units would require 36
patients per group (with 80% power and 5%
significance).
Although significant short-term differences were not
detected, the time to the next respiratory exacerbation
favoured the treatment group and the subsequent rate of
decline in lung function was less in subjects than
controls. Most of the immunological data also showed
greater improvement in the treatment group. A larger
multi-centre trial of TLC C-53 as an adjunct to antibiotic
therapy in respiratory exacerbations in CF would appear
warranted.
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